These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9354240)

  • 1. Abenzyl 10-formyl-trideazafolic acid (abenzyl 10-formyl-TDAF): an effective inhibitor of glycinamide ribonucleotide transformylase.
    Boger DL; Haynes NE; Warren MS; Ramcharan J; Marolewski AE; Kitos PA; Benkovic SJ
    Bioorg Med Chem; 1997 Sep; 5(9):1847-52. PubMed ID: 9354240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10-Formyl-5,8,10-trideazafolic acid (10-formyl-TDAF): a potent inhibitor of glycinamide ribonucleotide transformylase.
    Boger DL; Haynes NE; Kitos PA; Warren MS; Ramcharan J; Marolewski AE; Benkovic SJ
    Bioorg Med Chem; 1997 Sep; 5(9):1817-30. PubMed ID: 9354237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionalized analogues of 5,8,10-trideazafolate: development of an enzyme-assembled tight binding inhibitor of GAR Tfase and a potential irreversible inhibitor of AICAR Tfase.
    Boger DL; Haynes NE; Warren MS; Ramcharan J; Kitos PA; Benkovic SJ
    Bioorg Med Chem; 1997 Sep; 5(9):1839-46. PubMed ID: 9354239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionalized analogues of 5,8,10-trideazafolate as potential inhibitors of GAR Tfase or AICAR Tfase.
    Boger DL; Haynes NE; Warren MS; Gooljarsingh LT; Ramcharan J; Kitos PA; Benkovic SJ
    Bioorg Med Chem; 1997 Sep; 5(9):1831-8. PubMed ID: 9354238
    [No Abstract]   [Full Text] [Related]  

  • 5. A quantum chemical study on the mechanism of glycinamide ribonucleotide transformylase inhibitor: 10-Formyl-5,8,10-trideazafolic acid.
    Qiao QA; Jin Y; Yang C; Zhang Z; Wang M
    Biophys Chem; 2005 Dec; 118(2-3):78-83. PubMed ID: 16198047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase.
    Marsilje TH; Hedrick MP; Desharnais J; Capps K; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2003 Oct; 11(20):4503-9. PubMed ID: 13129586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.
    Marsilje TH; Labroli MA; Hedrick MP; Jin Q; Desharnais J; Baker SJ; Gooljarsingh LT; Ramcharan J; Tavassoli A; Zhang Y; Wilson IA; Beardsley GP; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2002 Aug; 10(8):2739-49. PubMed ID: 12057663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into inhibitor design from the crystal structure and NMR studies of Escherichia coli GAR transformylase in complex with beta-GAR and 10-formyl-5,8,10-trideazafolic acid.
    Greasley SE; Yamashita MM; Cai H; Benkovic SJ; Boger DL; Wilson IA
    Biochemistry; 1999 Dec; 38(51):16783-93. PubMed ID: 10606510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway.
    Cheng H; Hwang I; Chong Y; Tavassoli A; Webb ME; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2005 May; 13(10):3593-9. PubMed ID: 15848772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multisubstrate analogue based on 5,8,10-trideazafolate.
    Boger DL; Haynes NE; Warren MS; Ramcharan J; Kitos PA; Benkovic SJ
    Bioorg Med Chem; 1997 Sep; 5(9):1853-7. PubMed ID: 9354241
    [No Abstract]   [Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of simplified alpha-keto heterocycle, trifluoromethyl ketone, and formyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.
    Marsilje TH; Hedrick MP; Desharnais J; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2003 Oct; 11(20):4487-501. PubMed ID: 13129585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.
    Boger DL; Marsilje TH; Castro RA; Hedrick MP; Jin Q; Baker SJ; Shim JH; Benkovic SJ
    Bioorg Med Chem Lett; 2000 Jul; 10(13):1471-5. PubMed ID: 10888335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformationally restricted analogues designed for selective inhibition of GAR Tfase versus thymidylate synthase or dihydrofolate reductase.
    Boger DL; Labroli MA; Marsilje TH; Jin Q; Hedrick MP; Baker SJ; Shim JH; Benkovic SJ
    Bioorg Med Chem; 2000 May; 8(5):1075-86. PubMed ID: 10882019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
    Desharnais J; Hwang I; Zhang Y; Tavassoli A; Baboval J; Benkovic SJ; Wilson IA; Boger DL
    Bioorg Med Chem; 2003 Oct; 11(20):4511-21. PubMed ID: 13129587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
    Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of potential GAR and AICAR transformylase inhibitors.
    Boger DL; Kochanny MJ; Cai H; Wyatt D; Kitos PA; Warren MS; Ramcharan J; Gooljarsingh LT; Benkovic SJ
    Bioorg Med Chem; 1998 Jun; 6(6):643-59. PubMed ID: 9681131
    [No Abstract]   [Full Text] [Related]  

  • 17. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid.
    Zhang Y; Desharnais J; Marsilje TH; Li C; Hedrick MP; Gooljarsingh LT; Tavassoli A; Benkovic SJ; Olson AJ; Boger DL; Wilson IA
    Biochemistry; 2003 May; 42(20):6043-56. PubMed ID: 12755606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase.
    Greasley SE; Marsilje TH; Cai H; Baker S; Benkovic SJ; Boger DL; Wilson IA
    Biochemistry; 2001 Nov; 40(45):13538-47. PubMed ID: 11695901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human AICAR transformylase: role of the 4-carboxamide of AICAR in binding and catalysis.
    Wall M; Shim JH; Benkovic SJ
    Biochemistry; 2000 Sep; 39(37):11303-11. PubMed ID: 10985775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the cofactor specificity of glycinamide ribonucleotide and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase from chicken liver.
    Smith GK; Mueller WT; Benkovic PA; Benkovic SJ
    Biochemistry; 1981 Mar; 20(5):1241-5. PubMed ID: 7225325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.